Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Se...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2442720 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557039624486912 |
|---|---|
| author | Andrew Blauvelt Leon Kircik Todd Schlesinger Evangeline Pierce Russel Burge Michael Behling Amber Reck Atwater Hany ElMaraghy April Armstrong |
| author_facet | Andrew Blauvelt Leon Kircik Todd Schlesinger Evangeline Pierce Russel Burge Michael Behling Amber Reck Atwater Hany ElMaraghy April Armstrong |
| author_sort | Andrew Blauvelt |
| collection | DOAJ |
| description | Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc analysis).Methods In the 52-week (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive subcutaneous lebrikizumab 250 mg or placebo every 2 weeks. Investigator Global Assessment (IGA) 0/1 and improvements in QoL outcomes were assessed at W16 among lebrikizumab-treated patients.Results At W16, 564 patients were categorized by EASI response (EASI <50: 32.8%; EASI ≥50–<75: 13.8%; EASI ≥75–<90: 20.2%; EASI ≥90: 33.2%). Patients with higher EASI responses showed higher IGA 0/1 response rates (EASI ≥75–<90: 37.7% and EASI ≥90: 86.1%). Pruritus NRS (least squares mean range: −1.5 to −4.4), sleep-loss score (−0.6 to −1.6), and Dermatology Life Quality Index (−3.3 to −10.6) improved across EASI response categories (p < 0.001). Anxiety and depression scores improved for most EASI response categories (p < 0.01).Conclusion Lebrikizumab-treated patients with moderate-to-severe AD showed improved symptoms and QoL across EASI response categories at W16, with greater improvements observed in patients with higher EASI responses. |
| format | Article |
| id | doaj-art-baccaf25f52b411ab4a722d4c9d2cf8c |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-baccaf25f52b411ab4a722d4c9d2cf8c2025-01-07T00:57:36ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532025-12-0136110.1080/09546634.2024.2442720Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitisAndrew Blauvelt0Leon Kircik1Todd Schlesinger2Evangeline Pierce3Russel Burge4Michael Behling5Amber Reck Atwater6Hany ElMaraghy7April Armstrong8Blauvelt Consulting, LLC, Annapolis, MD, USAIcahn School of Medicine at Mount Sinai, New York, NY, USAClinical Research Center of the Carolinas, Charleston, SC, USAEli Lilly and Company, Indianapolis, IN, USAEli Lilly and Company, Indianapolis, IN, USASyneos Health, Morrisville, NC, USAEli Lilly and Company, Indianapolis, IN, USAEli Lilly and Company, Indianapolis, IN, USAKeck School of Medicine at University of California Los Angeles, Los Angeles, CA, USABackground Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Severity Index (EASI) response categories using pooled Advocate1 and ADvocate2 data (post hoc analysis).Methods In the 52-week (W) (16-W induction + 36-W maintenance) double-blind, placebo-controlled ADvocate1 and ADvocate2 studies, patients were randomized (2:1) to receive subcutaneous lebrikizumab 250 mg or placebo every 2 weeks. Investigator Global Assessment (IGA) 0/1 and improvements in QoL outcomes were assessed at W16 among lebrikizumab-treated patients.Results At W16, 564 patients were categorized by EASI response (EASI <50: 32.8%; EASI ≥50–<75: 13.8%; EASI ≥75–<90: 20.2%; EASI ≥90: 33.2%). Patients with higher EASI responses showed higher IGA 0/1 response rates (EASI ≥75–<90: 37.7% and EASI ≥90: 86.1%). Pruritus NRS (least squares mean range: −1.5 to −4.4), sleep-loss score (−0.6 to −1.6), and Dermatology Life Quality Index (−3.3 to −10.6) improved across EASI response categories (p < 0.001). Anxiety and depression scores improved for most EASI response categories (p < 0.01).Conclusion Lebrikizumab-treated patients with moderate-to-severe AD showed improved symptoms and QoL across EASI response categories at W16, with greater improvements observed in patients with higher EASI responses.https://www.tandfonline.com/doi/10.1080/09546634.2024.2442720Atopic dermatitislebrikizumabEczema Area and Severity Indexquality of life |
| spellingShingle | Andrew Blauvelt Leon Kircik Todd Schlesinger Evangeline Pierce Russel Burge Michael Behling Amber Reck Atwater Hany ElMaraghy April Armstrong Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis Journal of Dermatological Treatment Atopic dermatitis lebrikizumab Eczema Area and Severity Index quality of life |
| title | Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis |
| title_full | Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis |
| title_fullStr | Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis |
| title_full_unstemmed | Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis |
| title_short | Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis |
| title_sort | lebrikizumab is associated with improvements in patient reported symptoms and quality of life measures across eczema area and severity index response categories pooled results from phase 3 randomized advocate1 and advocate2 studies in patients with moderate to severe atopic dermatitis |
| topic | Atopic dermatitis lebrikizumab Eczema Area and Severity Index quality of life |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2442720 |
| work_keys_str_mv | AT andrewblauvelt lebrikizumabisassociatedwithimprovementsinpatientreportedsymptomsandqualityoflifemeasuresacrosseczemaareaandseverityindexresponsecategoriespooledresultsfromphase3randomizedadvocate1andadvocate2studiesinpatientswithmoderatetosevereatopicdermatitis AT leonkircik lebrikizumabisassociatedwithimprovementsinpatientreportedsymptomsandqualityoflifemeasuresacrosseczemaareaandseverityindexresponsecategoriespooledresultsfromphase3randomizedadvocate1andadvocate2studiesinpatientswithmoderatetosevereatopicdermatitis AT toddschlesinger lebrikizumabisassociatedwithimprovementsinpatientreportedsymptomsandqualityoflifemeasuresacrosseczemaareaandseverityindexresponsecategoriespooledresultsfromphase3randomizedadvocate1andadvocate2studiesinpatientswithmoderatetosevereatopicdermatitis AT evangelinepierce lebrikizumabisassociatedwithimprovementsinpatientreportedsymptomsandqualityoflifemeasuresacrosseczemaareaandseverityindexresponsecategoriespooledresultsfromphase3randomizedadvocate1andadvocate2studiesinpatientswithmoderatetosevereatopicdermatitis AT russelburge lebrikizumabisassociatedwithimprovementsinpatientreportedsymptomsandqualityoflifemeasuresacrosseczemaareaandseverityindexresponsecategoriespooledresultsfromphase3randomizedadvocate1andadvocate2studiesinpatientswithmoderatetosevereatopicdermatitis AT michaelbehling lebrikizumabisassociatedwithimprovementsinpatientreportedsymptomsandqualityoflifemeasuresacrosseczemaareaandseverityindexresponsecategoriespooledresultsfromphase3randomizedadvocate1andadvocate2studiesinpatientswithmoderatetosevereatopicdermatitis AT amberreckatwater lebrikizumabisassociatedwithimprovementsinpatientreportedsymptomsandqualityoflifemeasuresacrosseczemaareaandseverityindexresponsecategoriespooledresultsfromphase3randomizedadvocate1andadvocate2studiesinpatientswithmoderatetosevereatopicdermatitis AT hanyelmaraghy lebrikizumabisassociatedwithimprovementsinpatientreportedsymptomsandqualityoflifemeasuresacrosseczemaareaandseverityindexresponsecategoriespooledresultsfromphase3randomizedadvocate1andadvocate2studiesinpatientswithmoderatetosevereatopicdermatitis AT aprilarmstrong lebrikizumabisassociatedwithimprovementsinpatientreportedsymptomsandqualityoflifemeasuresacrosseczemaareaandseverityindexresponsecategoriespooledresultsfromphase3randomizedadvocate1andadvocate2studiesinpatientswithmoderatetosevereatopicdermatitis |